Nadecnemab

Description: Nadecnemab is an IGG4-kappaantibody targeting GFRA3, a receptor of the glial cell-derived neurotrophic factor family. Nadecnemab can be used for knee osteoarthritis and neurological disorders. Target: Others. References: Selin Somersan-Karakaya,et al.Monoclonal antibodies against GFRalpha3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain,Neurobiology of Pain,Volume 14,2023,100136,ISSN 2452-073X.